Every 10-Q that Lifevantage Corporation (LFVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFVN filings page.
LifeVantage Corporation reported lower sales and earnings for the quarter and nine months ended March 31, 2026. Quarterly net revenue fell to $43.7 million from $58.4 million, mainly from weaker MindBody GLP-1 System® demand in the Americas. Net income declined to $1.4 million from $3.5 million, though the business remained profitable.
For the nine months, revenue decreased to $140.2 million from $173.4 million, and net income dropped to $3.8 million from $7.8 million. Active Accounts fell 22.1% year over year, while the new LoveBiome® line and ongoing stock repurchases and dividends showed continued investment in the brand and shareholders.
LifeVantage Corporation reported weaker results for the quarter ended December 31, 2025 as revenue fell to $48.9 million from $67.8 million a year earlier, mainly from lower sales of its MindBody GLP-1 System™. Net income declined to $0.3 million from $2.6 million, with gross margin pressured by about $2.4 million of inventory obsolescence tied to this product line.
For the first six months, revenue was $96.5 million versus $115.0 million, and net income was $2.4 million versus $4.4 million. Active accounts fell 21.2% year over year to 115,000, reflecting fewer independent consultants and customers. The company completed a $4.2 million acquisition of LoveBiome assets, adding a new gut-health product line, and ended the period with $10.2 million in cash and no borrowings on its $5.0 million credit facility.
LifeVantage (LFVN) reported Q1 FY2026 results for the quarter ended September 30, 2025. Revenue was $47.6 million, up slightly from $47.2 million a year ago, as the MindBody GLP-1 System offset lower sales of Protandim and TrueScience. Gross profit was $37.8 million, a 79.5% margin.
Net income rose to $2.2 million from $1.8 million, with diluted EPS of $0.17 versus $0.14. The U.S. delivered $35.2 million in revenue, essentially flat, while Japan increased 3.5% to $6.2 million. Active Independent Consultants grew to 48,000, but total Active Customers declined to 73,000, bringing total Active Accounts to 121,000.
Cash and equivalents were $13.1 million, down from $20.2 million at June 30, 2025, reflecting $2.3 million used in operating activities, $0.6 million in cash dividends ($0.045 per share), and $0.6 million of share repurchases (44,000 shares). The company’s $5.0 million revolving credit facility had no balance outstanding; an amendment now permits use for acquisitions. On October 1, 2025, LifeVantage closed the acquisition of critical assets of LoveBiome, with purchase accounting pending.
Shares outstanding were 12,701,187 as of November 3, 2025.